A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.

NCT00423566 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
14
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Oxford